Tag:

M&A

Latest Headlines

Latest Headlines

Careful, European drugmakers. Fitch says M&A may be a bit too heated

Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.

Zimmer postpones closure of merger with Biomet

Zimmer announced that the "outside date" for completing its merger with Biomet has been postponed from April 24, 2015, to July 23, 2015.

Actavis says it'll lose $200M in Namenda sales if appeals court nixes a 'hard switch'

Actavis is trying to encourage an appeals court to let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda. Hundreds of millions in sales rest on the decision. But so far, the judges aren't offering any clues about their answer.

Clinipace bags CRO Accovion in its latest global buyout

Serial acquirer Clinipace has bought up European CRO Accovion, striking its 6th deal in as many years as it seeks to expand its global reach.

Roche snags a genomics startup with an eye on cancer R&D

Roche bought up a Stanford University-founded upstart with a promising approach to tracking the spread of cancer, eyeing a new tool in its expansive oncology R&D efforts.

Mylan seeks entry into animal health via $29B bid for Perrigo

When Mylan offered to buy Perrigo for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.

Will Mylan's $29B bid spur other Perrigo suitors to enter the fray?

More than a couple of analysts agree that there may be a company out there that's after Mylan--and that that could have prompted the company's $28.9 billion bid for Ireland's Perrigo. But now that Mylan's made its offer, could that spur other Perrigo offers, too?

Was Mylan's $29B Perrigo bid a takeover defense? Analysts say yes

Since Mylan went public on Wednesday with a $205-per-share buyout offer for Ireland's Perrigo, analysts have been weighing the pros and cons of a tie-up between the two generics makers. But there's one thing at least a few of them agree on: The $29 billion bid has to be a response to other M&A action going on behind the scenes.

Protea buys CRO vivoPharm for preclinical expertise

West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development.

Catalent reaches into Australia with latest buyout

Catalent is buying a drug packaging operation in Australia, extending its global reach with a focus on the Asia-Pacific region.